UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-QSB

(Mark One)
[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2007

[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

For the transition period from __________ to __________

COMMISSION FILE NUMBER: **333-101420**

ANTICUS INTERNATIONAL CORPORATION

(Exact name of small business issuer as specified in its charter)

Nevada	**98-0375504**
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification No.)

1155 Rene-Lévesque Ouest, Suite 2500
Montreal, Quebec, Canada H3B 2K4
(Address of principal executive offices)

(514) 992-1391
(Issuer's telephone number)

(Former name, former address and former fiscal year, if changed since last report)

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes [ ] No [X]

The number of shares outstanding of each of the issuer's classes of common equity as of March 31, 2007:
37,359,245 shares of common stock

Transitional Small Business Disclosure Format (check one): Yes [ ] No [X]

Index

ANTICUS INTERNATIONAL CORPORATION
(A DEVELOPMENT STAGE COMPANY)

BALANCE SHEET

		March 31, 2007 (Unaudited)
ASSETS		
Current assets		
Cash	$	777
Receivable from taxing authorities		6,189
		6,966
Other assets		
Intangible assets (Note 4)		593,736
Website development (Note 5)		6,575
		600,311
Total assets	$	607,277
Current liabilities		
Accounts payable and accrued expenses		99,058
Total liabilities		99,058
Stockholders' Equity		
Authorized common stock: 75,000,000 shares with a par value of $0.001		
Issued and outstanding: 37,359,245 common shares at March 31, 2007		37,359
Additional paid-in capital		1,537,934
Deficit accumulated during the development stage		(1,063,939)
Comprehensive (gain) loss		(3,135)
Total stockholders' equity		508,219
Total Liabilities and Stockholders' Equity	$	607,277

The accompanying notes are an integral part of these financial statements.

ANTICUS INTERNATIONAL CORPORATION
(A DEVELOPMENT STAGE COMPANY)

STATEMENTS OF OPERATIONS

	Three Month Period Ended March 31, 2007 (Unaudited)	Three Month Period Ended March 31, 2006 (Unaudited)	Nine Month Period Ended March 31, 2007 (Unaudited)	Nine Month Period Ended March 31, 2006 (Unaudited)	Cumulative Amounts from Date of Incorporation May 1, 2002 Through March 31, 2007 (Unaudited)
General and administrative expenses	$ 103,286	$ 41,545	$ 396,171	$ 222,681	$ 976,149
Other expenses					
Discontinued operations	-	-	-	87,790	87,790
Net loss for period	$ 103,286	$ 41,545	$ 396,171	$ 310,471	$ 1,063,939
Basic and diluted loss per common share	$ (0.00)	$ (0.00)	$ (0.01)	$ (0.01)	$ Nil
Weighted average number of shares outstanding	37,359,245	32,072,578	36,772,034	29,054,126	

The accompanying notes are an integral part of these financial statements.

ANTICUS INTERNATIONAL CORPORATION
(A DEVELOPMENT STAGE COMPANY)

STATEMENTS OF COMPREHENSIVE LOSS

	Three Months Ended March 31, 2007 (Unaudited)	Nine Months Ended March 31, 2007 (Unaudited)
Foreign currency translation adjustment	$ (1,039)	$ (3,135)

The accompanying notes are an integral part of these financial statements.

ANTICUS INTERNATIONAL CORPORATION
(A DEVELOPMENT STAGE COMPANY)

STATEMENTS OF CASH FLOWS

	Nine Month Period Ended March 31, 2007 (Unaudited)	Nine Month Period Ended March 31, 2006 (Unaudited)	Cumulative amounts from Date of Incorporation May 1, 2002 Through March 31, 2007 (Unaudited)
CASH FLOWS FROM OPERATING ACTIVITIES			
Net loss for the period	$ (396,171)	$ (310,471)	$ (1,063,939)
Shares issued for services	48,754	31,968	381,848
Compensation recognized on option grants	51,505	5,200	78,215
Amortization	121,664	-	139,628
Shares issued on abandoned license	-	-	76,000
Contributed rent and services	-	-	13,600
Adjustments to reconcile net loss to net cash used in operating activities			
Increase in accounts receivable	(6,188)	-	(6,188)
Decrease (increase) in prepaid expenses	-	900	-
Increase (decrease) in accounts payable	(13,518)	272,403	99,303
Net cash used in operating activities	(166,918)	-	(281,533)
CASH FLOWS FROM FINANCING ACTIVITIES			
Proceeds from issuance of common stock	40,000	-	293,630
Note payable to third party	(5,000)	-	-
Advances received from third party (paid)	(4,320)	-	-
Net cash provided by financing activities	30,680	-	293,630
CASH FLOWS FROM INVESTING ACTIVITIES			
Website development	(8,185)	-	(8,185)
Net cash used in investing activities	(8,185)	-	(8,185)
Effect of exchange rates on cash	(3,135)	-	(3,135)
Net change in cash	(147,558)	-	777
Cash at beginning of period	148,335	-	-
Cash at end of period	$ 777	$ Nil	$ 777
Supplemental disclosure with respect to cash flows			
Cash paid for income taxes	$ -	$ -	$ -
Cash paid for interest	$ -	$ -	$ -
Shares issued for debt settled (note 8(b))	$ -	$ 203,687	$ -
Shares issued for services (note 8(b))	$ 48,754	$ 31,968	$ 381,848
Shares issued for intangible assets (note 8(b))	$ 270,000	$ -	$ 808,000

The accompanying notes are an integral part of these financial statements.

Note 1 - Basis of Presentation

The accompanying interim financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC") for interim financial reporting. These interim financial statements are unaudited and, in the opinion of management, include all adjustments (consisting of normal recurring adjustments and accruals) necessary to present fairly the balance sheet, operating results and cash flows for the periods presented in accordance with accounting principles generally accepted in the United States of America ("GAAP"). Operating results for the three and nine months ended March 31, 2007 are not necessarily indicative of the results that may be expected for the year ending June 30, 2007 or for any other interim period during such year. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been omitted in accordance with the rules and regulations of the SEC. These interim financial statements should be read in conjunction with the audited financial statements and notes thereto contained in the Company's Form 10-KSB for the year ended June 30, 2006.

Note 2 – Nature of Operations

a) Organization
The Company was incorporated in the State of Nevada, U.S.A., on May 1, 2002.

b) Development stage activities
The Company is a development stage company as defined in the Statements of Financial Accounting Standards No. 7. The Company is devoting substantially all of its present efforts to establish a new business and none of its planned principal operations have commenced. All losses accumulated since inception have been considered as part of the Company's development stage activities.

The Company was formerly engaged in the development of specialized educational programs for the food services industry. The Company discontinued its involvement in these operations during the year.

c) Going concern
The accompanying financial statements have been prepared assuming the Company will continue as a going concern.

As shown in the accompanying financial statements, the Company has incurred a net loss of $1,063,939 for the period from inception, May 1, 2002 to March 31, 2007, and has no sales. The future of the Company is dependent upon its ability to obtain financing and upon future profitable operations. Management has plans to seek additional financing through a public offering of its common stock. The financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts of and classification of liabilities that might be necessary in the event the Company cannot continue in existence.

Note 3 – Significant Accounting Policies

The financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States. The application of Canadian generally accepted accounting principles to these financial statements would not result in material measurement or disclosure differences. Because a precise determination of many assets and liabilities is dependent upon future events, the preparation of financial statements for a period necessarily involves the use of estimates, which have been made using careful judgment.

The financial statements have, in management's opinion, been properly prepared within reasonable limits of materiality and within the frame work of the significant accounting policies summarized below:

a) Organizational and start-up costs
Costs of start-up activities, including organizational costs, are expensed as incurred.

b) Foreign currency translation
Transaction amounts denominated in foreign currencies are translated at exchange rates prevailing at transaction dates. Carrying values of monetary assets and liabilities are adjusted at each balance sheet date to reflect the exchange rate at that date. Non-monetary assets and liabilities are translated at the exchange rate on the original transaction date. Gains and losses from restatement of foreign currency monetary and non-monetary assets and liabilities are included in the statement of operations. Revenues and expenses are translated at the rates of exchange prevailing on the dates such items are recognized in the statement of operations.

c) Income taxes
The Company follows Statement of Financial Accounting Standards No. 109 – "Accounting for Income Taxes". This standard requires the use of an asset and liability approach for financial accounting and reporting on income taxes. If it is more likely than not that some portion or all of a deferred tax asset will not be realized, a valuation allowance is recognized.

d) Basic and diluted loss per share
The Company reports earnings (loss) per share in accordance with SFAS No. 128, "Earnings per Share." Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted earnings (loss) per share has not been presented since the effect of the assumed conversion of options to purchase common shares would have an anti-dilutive effect. The only potential common shares as of March 31, 2007 were 600,000 options that have been excluded from the computation of diluted net loss per share because the effect would have been anti-dilutive. If such shares were included in diluted EPS, they would have resulted in weighted-average common shares of 37,856,467 and 33,168,689 for the three-months ended March 31, 2007. Diluted EPS for the nine-months ended March 31, 2007 and 2006 amounted to 37,160,356 and 32,120,043, respectively.

e) Issuances involving non-cash consideration
All issuances of the Company's stock for non-cash consideration have been assigned a dollar amount equaling either the market value of the shares issued or the value of consideration received, whichever is more readily determinable. The majority of non-cash consideration received pertains to services rendered by consultants and others.

f) Cash and cash equivalents
For purposes of the statement of cash flows, the Company considers cash and cash equivalents to include all stable, highly liquid investments with maturities of three months or less.

g) Website Development Costs
Under FASB Emerging Issues Task Force Statement 00-2, Accounting for Web Site Development Costs ("EITF 00-2"), costs and expenses incurred during the planning and operating stages of the Company's web site development are expensed as incurred. Under EITF 00-2, costs incurred in the web site application and infrastructure development stages are capitalized by the Company and amortized to expense over the web site's estimated useful life or period of benefit.

h) Use of estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

i) Fair value of financial instruments
Pursuant to SFAS No. 107, "Disclosures About Fair Value of Financial Instruments", the Company is required to estimate the fair value of all financial instruments included on its balance sheet as of March 31, 2007. The Company considers the carrying value of such amounts in the financial statements to approximate their fair value.

i) Long-lived assets
The Company accounts for its long-lived assets in accordance with SFAS No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets". SFAS No. 144 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the historical cost carrying value of an asset may no longer be appropriate. The Company assesses recoverability of the carrying value of an asset by estimating the future net cash flows expected to result from the asset, including eventual disposition. If the future net cash flows are less than the carrying value of the asset, an impairment loss is recorded equal to the difference between the asset's carrying value and the fair value or disposal value. As of March 31, 2007, the Company does not believe there has been any impairment of its long-lived assets.

j) New accounting standards

SFAS No. 159 - In February 2007, the FASB issued Statement No. 159, *The Fair Value Option for Financial Assets and Financial Liabilities—Including an amendment of FASB Statement No. 115***.** This Statement permits entities to choose to measure many financial instruments and certain other items at fair value. The objective is to improve financial reporting by providing entities with the opportunity to mitigate volatility in reported earnings caused by measuring related assets and liabilities differently without having to apply complex hedge accounting provisions. This Statement is expected to expand the use of fair value measurement, which is consistent with the Board's long-term measurement objectives for accounting for financial instruments. This Statement applies to all entities, including not-for-profit organizations. Most of the provisions of this Statement apply only to entities that elect the fair value option. However, the amendment to FASB Statement No. 115, *Accounting for Certain Investments in Debt and Equity Securities,* applies to all entities with available-for-sale and trading securities. Some requirements apply differently to entities that do not report net income. This Statement is effective as of the beginning of an entity's first fiscal year that begins after November 15, 2007. Early adoption is permitted as of the beginning of a fiscal year that begins on or before November 15, 2007, provided the entity also elects to apply the provisions of FASB Statement No. 157, *Fair Value Measurements.* No entity is permitted to apply this Statement retrospectively to fiscal years preceding the effective date unless the entity chooses early adoption. The choice to adopt early should be made after issuance of this Statement but within 120 days of the beginning of the fiscal year of adoption, provided the entity has not yet issued financial statements, including required notes to those financial statements, for any interim period of the fiscal year of adoption. This Statement permits application to eligible items existing at the effective date (or early adoption date). The Company has evaluated the impact of the implementation of SFAS No. 159 and does not believe the impact will be significant to the Company's overall results of operations or financial position.

Note 4 – Intangible Assets

In December 2005, the Company signed a Letter of Intent with MD Technologies Inc., Costal Inc., and Redal Inc. to acquire the worldwide exclusive license to the microbiological process known as "Prolactis". The process provides for the bioconversion of lactose and other sugar into high proteins biomass, literally transforming waste and by-products into water and yeast to be used in animal feed.

The license was issued to the Company effective April 20, 2006. As compensation for the license, the Company issued two million one hundred thousand (2,100,000) shares at $0.20 per share, that were issued as an exempted transaction under Section 4(2) of the Securities Act of 1933. In and subject to Rule 144 of the Securities Act of 1933 and in conjunction with the acquisition of the license, the Company paid a finder's fee of two hundred and ten thousand (210,000) shares also valued at $0.20 per share. On October 3, 2006, the Company issued 1.5 million (1,500,000) shares at $0.18 per share to the licensor to waive any and all conditions contained in the license agreement and obtain a clear title to *Prolactis*. The cost of the license of $732,000 is being amortized over five years. Amortization expense for the three-month and nine-month period ended March 31, 2007 were $36,600 and $120,300 respectively. The balance of the intangible asset as of March 31, 2007 was $593,736.

Amortization expense for each of the next five years is as follows:

March 31,	
2008	$ 146,400
2009	$ 146,400
2010	$ 146,400
2011	$ 146,400
2012	$ 8,136

Note 5 – Website Development

The cost of the website amounted to $7,890 is being amortized over three years. Amortization expense for the three-month and nine-month period ended March 31, 2007 were $682 and $1,364 respectively. The balance of website development as of March 31, 2007 was $6,575.

Amortization expense for each of the next three years is as follows:

March 31,

2008	$ 2,360
2009	$ 2,360
2010	$ 1,855

Note 6 – Capital Stock

a) Stock split

On August 19, 2004, the Company effected a 3:1 forward stock split. The issued and outstanding common stock after split became 10,050,000. On November 18, 2004, the Company effected a 3:1 forward stock split; the issued and outstanding common stock after the split became 30,150,000. The authorized capital stock remained at 75,000,000 shares.

All references in the accompanying financial statements to the number of common shares and per-share amounts have been restated to reflect the forward stock split.

b) Common stock issuances

On July 1, 2005, the Company issued 799,265 shares of its common stock to two of its attorneys and 125,000 shares of its common stock to a consultant. The 924,265 shares were valued at $138,309.

On July 12, 2005, the Company issued 50,000 shares of its common stock for legal services valued at $6,000.

On July 19, 2005, the Company issued 66,286 shares of its common stock for legal services valued at $13,257.

On July 27, 2005, the Company issued 52,669 shares of its common stock for consulting services valued at $13,168.

On July 28, 2005, the Company issued 100,000 shares of its common stock in connection with the development of encryption software to be utilized on movies. The shares were valued at $24,000. The software project subsequently was abandoned.

On September 2, 2005, the Company issued 200,000 shares of its common stock in connection with the development of encryption software to be utilized on movies. The shares were valued at $52,000. The software project subsequently was abandoned.

On September 7, 2005, the Company issued 195,692 shares of its common stock for legal services valued at $50,880. Also on September 7, 2005, the Company issued 33,180 shares for consulting services valued at $8,627.

On October 11, 2005, the Company issued 171,872 shares of its common stock for legal services valued at $29,218.

On January 27, 2006, the Company issued 172,765 shares of its common stock for legal services valued at $14,685.

On January 30, 2006, the Company issued 200,000 shares of its common stock for legal services valued at $18,000.

On April 18, 2006, the Company issued 227,500 shares of its common stock for legal services valued at $40,950.

On April 20, 2006, the Company issued a total of 2,310,000 shares of its common stock for the worldwide exclusive license to the microbiological process known as “Prolactis”. The license was valued at $462,000.

On May 31, June 12 and June 15, 2006, the Company issued 645,000 shares of its common stock in private offering for $161,631

On August 14, 2006, the Company issued 75,016 shares of its common stock for legal services valued at $18,754.

On August 17, 2006, the Company issued 100,000 shares of its common stock in a private offering for $25,000.

On August 21, 2006, the Company issued 125,000 shares of its common stock for legal services valued at $30,000.

On August 31, 2006, the Company issued 60,000 shares of its common stock in a private offering for $15,000.

On October 3, 2006 the Company issued a total of 1,500,000 shares of its common stock for the waiving of all conditions in the license agreement, giving a clear title to *Prolactis,* valued at $270,000.

c) Stock options

The Company has a stock option plan under which directors are authorized to grant incentive stock options, to a maximum of three million (3,000,000) of the issued and outstanding shares, to directors, employees and consultants of the Company entitling them to purchase common shares.

Compensation costs attributable to share options granted to employees, directors or consultants is measured at fair value at the grant date and expensed with a corresponding increase to additional paid-up capital.

During the year ended June 30, 2006, a total of 300,000 options were granted to two (2) directors, of which 100,000 was cancelled and reissued under modified terms, as follows:

On October 12, 2005, the board approved compensation to PH Vincent consisting of 100,000 options expiring December 31, 2007 at a price of $0.17 per share; these options were re-priced and reissued to be consistent with the 100,000 options granted at a price of $0.085 per share to Gilles Varin on January 23, 2006 and expiring on December 31, 2007. On April 19, 2006 each director received an additional 50,000 options at a price of $0.19 per share expiring December 31, 2007.

On August 30, 2006, the Company agrees to pay Mr. Trudeau compensation of five hundred thousand (500,000) options expiring June 30, 2008, exercisable at US$0.24, said options to be vested according to the following schedule:

125,000 December 15, 2006
125,000 March 15, 2007
125,000 June 15, 2007
125,000 September 15, 2007

On October 3, 2006, the board approved compensation to PH Vincent consisting of 50,000 options expiring December 31, 2007 at a price of $0.18 per share.

During the three-month and nine-month period March 31, 2007, the recognized compensation expense associated with options granted were valued at $22,550 and $51,505 respectively, which was charged to operations.

The following is a summary of the outstanding options:

	Number of Shares	Weighted Average Exercise Price
Outstanding – June 30, 2005	-	-
Granted	400,000	$ 0.13
Exercised	-	-
Cancelled	(100,000)	0.17
Outstanding – June 30, 2006	300,000	0.12
Granted	300,000	$ 0.23
Exercised	-	-
Cancelled	-	-
Outstanding – March 31, 2007	600,000	0.18

All of the outstanding options can be exercised through June 30, 2008 at a price per share ranging from $0.085 to $0.24. The fair value of each option granted is estimated at the respective grant date using the Black-Scholes Option Module. Options granted during the three months and nine months ended March 31, 2007 were valued at $22,550 and $51,505, respectively, which were charged to operations. The following assumptions were made in estimating fair value:

Dividend Yield	0%
Expected Life	2 years
Risk Free Interest Rate	4.34 % - 4.90 %
Expected Volatility	101 % - 187 %

Note 7 – Contingencies

The Company acquired the rights to enter into a merger agreement with Deltacrypt Technologies Inc. (“Delta”), a Canadian-based technology developer and provider of versatile encryption technology. Anticus acquired the rights to merge with Delta from 610051 N.B. Inc. (a private Canadian Corporation) which entered into an agreement with Delta regarding the merger of Delta into a public company (the “Agreement”). The rights were acquired through the issuance of 300,000 shares of the Company’s common stock valued at $76,000.

The agreement was contingent upon Anticus providing a minimum of $750,000 of additional capital.

The Company’s agreement to acquire Deltacrypt was modified on September 8, 2005, and under the modified terms, the Company agreed to make advances to Deltacrypt estimated at $27,000 CDN (or approximately $23,000 in US dollars) per month from August 1, 2005 to fund Deltacrypt operations until full completion of the merger. All funds advanced are to be applied to the condition requiring Anticus to provide a minimum of $750,000 of available capital to Deltacrypt at the close of the merger. The Company terminated this agreement with Deltacrypt and has only paid $10,000 towards this obligation. The Company has not established any reserve for any amounts which may be due to Deltacrypt under the agreement.

Note 8 – Restatement of Prior Periods

The Company discovered that it had inadvertently omitted certain transactions that occurred in its attorney's trust account during the year ended June 30, 2006. The June 30, 2006 balance sheet has been restated to correct these errors, and is presented as part of the basic financial statements in this filing. Additionally, certain costs associated with the Company's termination of its merger agreement with Delacrypt (see note 9) were not originally classified as a discontinued operating component in the March 31, 2006 quarterly financial statements. A summary of the restatements follows:

	June 30, 2006 as originally stated	June 30, 2006 as restated	Change
Balance sheet			
Cash held in Trust	$ -	$ 148,335	$ 148,335
Accounts payable	(89,081)	(85,756)	3,325
Common stock	(34,854)	(35,499)	(645)
Additional paid-in capital	(968,549)	(1,129,535)	(160,986)
Deficit accumulated during the development stage	657,768	667,768	10,000
Comprehensive (gain) loss	-	(29)	(29)
	$ (434,716)	$ (434,716)	$ Nil

	Nine month period ended March 31, 2006	Nine month period ended March 31, 2006 as restated	Change
Statement of operations			
Loss from continuing operations	$ 310,471	$ 222,681	$ 87,790
Loss from operations of discontinued component	-	87,790	(87,790)
Net loss for the period	$ 310,471	$ 310,471	$ -

Note 9 – Subsequent Events

On April 12, 2007, the Company commenced a private offering of 5,714,286 units at a price of $.07 per unit. Each unit consists of one share of the Company's common stock, a Class A Warrant to purchase one share of the Company common stock at a price of $.12 per share. The warrant expires on or before May 1, 2008. The offering also provides that a Class B Warrant will be issued to those who exercise their Class A Warrants. The Company plans to place all funds raised through the offering in escrow until the full $400,000 is raised. If the full amount of the offering is not raised prior to the closing date of May 31, 2007, the amounts placed in escrow will be returned without interest.

Item 2. Management's Discussion and Analysis of Financial Condition and Plan of Operations

This statement may include projections of future results and "forward looking statements" as that term is defined in Section 27A of the Securities Act of 1933 as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934 as amended (the "Exchange Act"). All statements that are included in this Quarterly Report, other than statements of historical fact, are forward looking statements. Although management believes that the expectations reflected in these forward looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct.

Financial Summary

Results of Operations for the Three-Month and Nine-Month periods ended March 31, 2007

The Company reports a net loss of $103,286 for the three-months ended March 31, 2007 versus a net loss of $41,545 for the three-months ended March 31, 2006. The net loss for the three-months ended March 31, 2007 is entirely comprised of loss from general and administrative expenses.

The Company reports a net loss of $393,171 for the nine-months ended March 31, 2007 versus a net loss of $310,471 for the nine-months ended March 31, 2006. The net loss for the nine-months ended March 31, 2007 is entirely comprised of loss from general and administrative expenses.

Liquidity and Capital Resources

During the nine-month period ended March 31, 2007 the Company's cash position decreased $147,558. Net cash used in operating activities totaled $166,918; $8,185 was used in investing activities; and $30,680 was provided by financing activities, primarily from the issuance of common stock.

Going Concern

The Company has incurred a net loss of $1,063,939 for the period from inception, May 1, 2002 to March 31, 2007, and has no sales. The future of the Company is dependent upon its ability to obtain financing and upon future profitable operations. Management has plans to seek additional financing through a private or public offering of its common stock. There is substantial doubt as to our ability to continue as a going concern. Our auditors have made reference to the substantial doubt about our ability to continue as a going concern in their audit report on our audited financial statements for the year ended June 30, 2006.

Management Plan of Operations

In December 2005, the Company signed a Letter of Intent with MD Technologies Inc., Costal Inc., and Redal Inc. to acquire the worldwide exclusive license to the microbiological process known as "Prolactis". The process provides for the bioconversion of lactose and other sugar into high proteins biomass, literally transforming waste and by-products into water and yeast to be used in animal feed.

The license was issued to the Company effective April 20, 2006. As compensation for the license, the Company issued two million one hundred thousand (2,100,000) shares of its common stock valued at $0.20 per share.

On October 3, 2006, the Company issued 1.5 million (1,500,000) shares at $0.18 per share to the licensor to waive any and all conditions contained in the license agreement and obtain a clear license to *Prolactis*. The cost of the license of $732,000 is being amortized over five years. .

The *Prolactis* process provides, through the use of a bioreactor, for the bioconversion of lactose and other sugar, into high proteins biomass, literally transforming waste and by products into water and yeast to be used in animal feed. The Process has been developed by Jacques Goulet, Ph.D., agr., professor at Laval University in Quebec City, Quebec, Michel Deblois, engineer, and Lucien Pomerleau, M.Sc., agr. Worldwide patents are pending.

Anticus is now obligated to pay Redal, Inc. a royalty of four percent (4%) of all gross sales. Redal, Inc. holds the exclusive right to supply the proprietary components of the systems, at fair values to be agreed between the parties.

Daniel Trudeau, our president has been working to develop a comprehensive business plan to commercialize our exclusive license to the microbiological process known as "Prolactis."

The firm of Dupuis Anger was hired to evaluate the potential markets for our yeast product. They presented the first part of their report in February 2007. It confirms some of our prior assumptions related to our business plan.

The market can be divided in three segments; the animal feed market, the pet food market and the food and ingredient market. The product can be divided into two parts; inactive whole cell yeast, and, Autolyzed yeast (the whole cell material is present but has been partially broken down).

North American use for these two yeast products, where most producers of yeast are selling to USA and Canada was:

> Whole cell yeast; Dried, and as inactive yeast range from 9,000 metric tons to 12,000 metric tons annually.
>
> Autolyzed Yeast; This is yeast that has been treated or inactivated by addition of salt or sometimes a chemical like an alkali to perforate the cell wall and cell membrane. Due to the perforation, the interior contents "spill" out and are more readily available for flavor delivery when dried. Annual volume is 1,000 to 1,500 metric tons per year.

The second part of the market study is expected in June of 2007.

Mr. Trudeau and our Chairman have been developing a financing plan to facilitate the commercialization of our proprietary process.

Our first phase of this plan commenced on April 12, 2007, When the Company commenced a private offering for up to $400,000; the Company has placed all funds raised through the offering in escrow until the full $400,000 is raised. A 6% finder's fee may be paid from the proceeds. If the full amount of the offering is not raised prior to the closing date of May 31, 2007, the amounts placed in escrow will be returned without interest. As of the date of this report on Form 10QSB the company is holding approximately $390,000 and expects to complete the offering and accept the total proceeds soon.

The Company will use the proceeds from this offering to build a single bioreactor to produce yeast samples for testing, analysis and sales promotion. A portion will also be used for general business obligations.

Our New Process

The process relies on the capacity of yeast to absorb and digest components of polluting elements dissolved in liquids. Main elements researched are carbon and nitrogen under a special form which allow yeast to reproduce. Multiple agricultural food rejects contain either nitrogen or carbon or even both. These food by-products have no value and create problems for disposal. Yeast produced from the waste materials can be sold based on grade and composition at various pricing. This value is variable and can be ranged, for example, from animal food to pharmaceutical applications.

A very high amount of yeast organisms (Billions by square Meters) are placed in the bioreactor of the ProLactis process. They are called Mother cells. The bioreactor is fed continuously (24h/day, 7 days a week) from the top with the liquid to be treated which has been mixed with nutritive complements. This mixture provides the yeast a balanced nutrition necessary for an optimal production. The daughter cells resulting from the growth and subdivision of the mother cells placed in the bioreactor free themselves and are transported by the flowing liquid. As a result, the liquid exiting from the bioreactor is less pollutant and contains a great number of new yeast cells. These are then recuperated, concentrated and dried according to customer requirements.

The bioreactor has been developed by Jacques Goulet et Michel DeBlois. It is under international patent pending. The other equipment required for the entire process is commercially used by yeast makers (funnels, pumps, drier, centrifugal etc.)

Licenses/Patents

Anticus holds an exclusive license to the microbiological process known as "Prolactis". The process provides for the bioconversion of lactose and other sugar into high proteins biomass, literally transforming waste and by-products into water and yeast to be used in animal feed. The underlying patent application is identified as United States Patent application # US 2005/0037452 published February 17, 2005,

Item 3. Controls and Procedures

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Based on this evaluation, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures were effective as the end of the period covered by this report. There were no changes in our internal control over financial reporting during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

Part II. OTHER INFORMATION

Item 1. Legal Proceedings

None, for the three-month period ended March 31, 2007

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None, for the three-month period ended March 31, 2007

On April 12, 2007, the Company commenced a private offering of 5,714,286 units at a price of $.07 per unit. Each unit consists of one share of the Company's common stock, a Class A Warrant to purchase one share of the Company common stock at a price of $.12 per share. The warrant expires on or before May 1, 2008. The offering also provides that a Class B Warrant will be issued to those who exercise their Class A Warrants.

The Company has placed all funds raised through the offering in escrow until the full $400,000 is raised. If the full amount of the offering is not raised prior to the closing date of May 31, 2007, the amounts placed in escrow will be returned without interest. As of the date of this report on Form 10QSB the company is holding approximately $390,000 and expects to complete the offering and accept the total proceeds soon. The company will pay a finder's fee of 6% from the proceeds.

The Company will use the proceeds from this offering to build a small bioreactor to produce yeast samples for testing, analysis and sales promotion. A portion will also be used for general business obligations.

All shares were issued as exempted transactions under Section 4(2) of the Securities Act of 1933, Regulation S and are subject to Rule 144 of the Securities Act of 1933. The recipient(s) of our stock took their shares for investment purposes without a view to distribution. Furthermore, they had access to information concerning our Company and our business prospects; there was no general solicitation or advertising for the purchase of our shares; there were no commissions paid; and the securities are restricted pursuant to Rule 144.

Common stock options

On August 30, 2006, the Company agreed to pay Mr. Trudeau, our President, compensation of five hundred thousand (500,000) options expiring June 30, 2008, exercisable at US$0.24, said options to be vested according to the following schedule:

125,000 December 15, 2006
125,000 March 15, 2007
125,000 June 15, 2007
125,000 September 15, 2007

All options were issued as exempted transactions under Section 4(2) of the Securities Act of 1933, Regulation S and are subject to Rule 144 of the Securities Act of 1933. The recipient(s) of our stock options took them for investment purposes without a view to distribution. Furthermore, they had access to information concerning our Company and our business prospects; there was no general solicitation or advertising; there were no commissions paid; and the securities issued upon exercise will be restricted pursuant to Rule 144.

Item 3. Defaults Upon Senior Securities

None

Item 4. Submission of Matters to a Vote of Security Holders

None, for the three-month period ended March 31, 2007

Item 5. Other Information

None

Item 6. Exhibits and Reports on Form 8-K

Exhibits

Anticus International Corporation includes herewith the following exhibits:

31.1 Certification of Principal Executive Officer (Rule 13a-14(a)/15(d)-14(a))
32.1 Certification of Principal Executive Officer (18 U.S.C. 1350)

Reports on Form 8-K

None, for the three-month period ending March 31, 2007

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Anticus International Corporation

Date: May 15, 2007

By: /s/ Daniel Trudeau, President
Daniel Trudeau, President
Principal Executive Officer
Principal Accounting Officer